Ophidion is a biotechnology company focused on developing brain-targeted therapies for neurodegenerative and anxiety-related disorders. The company utilizes a Trojan horse strategy to deliver small molecule drugs and biologics into the brain, primarily aiming to address neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases.
Ophidion's platform technology enables the delivery of a wide range of drugs, including gene therapeutics, siRNAs, antibodies, and peptides. Furthermore, the company is preparing for pivotal clinical trials to address anxiety-related disorders, accompanied by a patented companion biomarker diagnostic to identify suitable patient populations. Founded in 2008, Ophidion operates in the Biotechnology and Health Care industries. Its latest funding round consisted of a Convertible Note investment on 24 May 2023, with Robin Hood Ventures participating as the investor.
